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The family of membrane protein called glutamate receptors play an important role in the
central nervous system in mediating signaling between neurons. Glutamate receptors
are involved in the elaborate game that nerve cells play with each other in order to
control movement, memory, and learning.
Neurons achieve this communication by rapidly converting electrical signals into
chemical signals and then converting them back into electrical signals. To propagate an
electrical impulse, neurons in the brain launch bursts of neurotransmitter molecules like
glutamate at the junction between neurons, called the synapse. Glutamate receptors
are found lodged in the membranes of the post-synaptic neuron. They receive the burst
of neurotransmitters and respond by fielding the neurotransmitters and opening ion
channels.
Glutamate receptors have been implicated in a number of neuropathologies like
ischemia, stroke and amyotrophic lateral sclerosis. Specifically, the NMDA subtype of
glutamate receptors has been linked to the onset of Alzheimer’s disease and the
subsequent degeneration of neuronal cells.

While crystal structures of AMPA and

kainate subtypes of glutamate receptors have provided valuable information regarding
the assembly and mechanism of activation; little is known about the NMDA receptors.
Even the basic question of receptor assembly still remains unanswered. Therefore, to
v

gain a clear understanding of how the receptors are assembled and how agonist
binding gets translated to channel opening, I have used a technique called
Luminescence Resonance Energy Transfer (LRET). LRET offers the unique advantage
of tracking large scale conformational changes associated with receptor activation and
desensitization. In this dissertation, LRET, in combination with biochemical and
electrophysiological studies, were performed on the NMDA receptors to draw a
correlation between structure and function. NMDA receptor subtypes GluN1 and
GluN2A were modified such that fluorophores could be introduced at specific sites to
determine their pattern of assembly. The results indicated that the GluN1 subunits
assembled across each other in a diagonal manner to form a functional receptor. Once
the subunit arrangement was established, this was used as a model to further examine
the mechanism of activation in this subtype of glutamate receptor. Using LRET, the
correlation between cleft closure and activation was tested for both the GluN1 and
GluN2A subunit of the NMDA receptor in response to agonists of varying efficacies.
These investigations revealed that cleft closure plays a major role in the mechanism of
activation in the NMDA receptor, similar to the AMPA and kainate subtypes. Therefore,
suggesting that the mechanism of activation is conserved across the different subtypes
of glutamate receptors.
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Chapter 1—Introduction: Ionotropic Glutamate Receptors
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I.

Ion Channels- Glutamate Receptors

The complexity of glutamate as a signaling molecule and as an excitatory
neurotransmitter has been a major subject of study for more than 50 years (1).
Glutamate released in synaptic pockets induces its effect by interacting with specialized
membrane proteins embedded in the post synaptic membrane called glutamate
receptors (2). Glutamate receptors are subdivided into two major subtypes: Ionotropic
glutamate receptors (iGluRs) form integral ligand - gated ion channels and metabotropic
glutamate receptors (mGluRs) that activate G- proteins via a secondary messenger
system (3, 4). This thesis will focus on iGluRs.
iGluRs are major mediators of excitatory signal transmission in the mammalian central
nervous system (5). Glutamate, upon binding to the receptor induces formation of ion
channels and thereby enables cations like sodium, potassium and sometimes calcium
to flow through the membrane (1, 6). Based on their pharmacological properties; iGluRs
are divided into three major receptor families: α-amino-5-methyl-3-hydroxy-4-isoxazole
propionate (AMPA) receptors, N-methyl-D-aspartate (NMDA) and Kainate receptors (3).
Although the three receptor subtypes share a similar subunit topology, their overall
structure, function and ligand affinity differ across each subtype (7-9).
In 1998, Roderick Mackinnon solved the first structure of the voltage gated K+ channel
that described the mechanism of ion channel selectivity by the pore region of the
receptor (10). This discovery has paved the way for the identification of numerous ion
channel crystal structures in the last decade. In 2009, Eric Gouaux and co- workers
solved the first crystal structure of the full length AMPA receptor subunit (GluA2) and
revealed the intricate architecture of the glutamate receptor family (11). This structure
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along with the multitude of soluble ABD structures has helped delineate the mechanism
of activation of the AMPA subtype of glutamate receptors. However such information
for the NMDA subtype of glutamate receptors is still largely amiss, and with just a
handful of structures available on the ABD of GluN1 and just one for the GluN2A
subunit, these receptors still remain an enigma in the ion channel field (12-14). Given
their role in the modulation of numerous physiological processes there is a tremendous
need to understand the molecular mechanism of the NMDA receptor activation. Even
the basic question of subunit assembly is unknown for this receptor. In my dissertation, I
am presenting the use of LRET as a molecular ruler to determine the specific subunit
arrangement of a functional NMDA receptor and established the mechanism of
activation in this receptor family.
II.

Ionotropic Glutamate receptors subtypes:

iGluRs, based on their pharmacology are subdivided into three major types of receptors,
AMPA, NMDA and Kainate(3). While AMPA receptors bind to AMPA (a synthetic ligand)
as a full agonist, NMDA receptors bind to NMDA (another synthetic ligand) as a full
agonist, lastly Kainate receptors bind to Kainate (a natural toxin present in sea weed) as
a full agonist (15). There is a unique role for each of the receptors in this family. AMPA
receptors play a vital role in mediating rapid excitatory synaptic current in the brain (16).
NMDA receptors act as coincidence detectors, monitoring changes in glutamate
concentrations in the synaptic cleft and variations in membrane potential (17). Kainate
receptors play a modulatory role both at presynaptic and synaptic cleft (18). The
receptors are further subdivided into different subunits (Figure 1). While AMPA
receptors are composed of subunits GluA1-4 (3, 4, 8, 19, 20), and Kainate receptor
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Figure 1 Subtypes of the eukaryotic ionotropic glutamate receptors based on their
pharmacology.
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GluA5-7 (19, 20), KA1-2 are capable of forming homo or hetero - tetramers, the NMDA
receptors are primarily composed of subunits GluN1, GluN2A-D and GluN3 subunits
(21-24). They are obligate hetero tetramers. In addition, while non NMDA receptors can
be activated solely by glutamate, NMDA receptors require both glycine and glutamate
for full activation (23, 25, 26). Other than their importance in mediating excitatory
synaptic transmission in the CNS, these receptors are also involved in neuronal
development, synaptogenesis and neuronal viability (27, 28). Excitotoxicity or excessive
activation of these receptors results in neuronal damage, which in turn is linked to
various neuropathologies like ischemia, stroke, Alzheimer’s, Parkinson’s and seizures
etc (29, 30). In addition to their involvement in the CNS, these receptors are further
found expressed in several other tissues: insulin secretion in pancreatic islet cells
express glutamate receptor, bone re absorption in osteoblasts, cardiac pacemaking in
cardiac ganglia cells, and nerve terminals in skin where glutamate receptors participate
in pain perception and tactile sensation (31, 32). Their broad distribution among
different cell types thus makes them an ideal candidate for drug investigations.
III. Subtype of Glutamate Receptors: Molecular properties of NMDA Receptors
NMDA receptors, a major subtype of iGluRs have been studied extensively for the last
two decades since their discovery in the 1980’s (23). They are widely distributed
throughout the CNS and play a vital role in establishing neuronal connection early
during development. While in adults, NMDA receptors are involved in the modulation of
synaptic strength and learning and memory (23). Therefore, regulation of these
receptors is vital.
a. Splice variants and subunit composition
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Three subunits of the NMDA receptor have been identified, GluN1, GluN2 and GluN3
(24, 25, 33). The glycine binding GluN1 subunit has one gene product with eight splice
variants, while the glutamate binding GluN2 subunit has four gene products, GluN2A-D
(25, 34). The GluN3 subunit of the NMDA receptor consists of two gene products
GluN3A-B and can form functional receptor in combination with GluN1. A functional
receptor is formed by a combination of GluN1 subunits with any of the glutamate
binding GluN2 subunits (24, 35, 36). Each subunit is characterized by unique activation
and desensitization kinetics. The open channel probability of the subunits differs
markedly with GluN2A containing receptors having the maximum channel open
probability (37, 38).
b. Expression pattern of subunits
There is a general shift in the trend of subunit expression from GluN2B and GluN2D to
GluN2A and GluN2C receptor predominance during development. GluN2B and GluN2D
subunit expression is found as early as in the embryonic stage while the pattern of
expression upon maturity in the adult brain is typically GluN2A containing receptors,
except in the forebrain region (39). While GluN2A expression is not limited, GluN2C
expression is limited to the cerebellum during adulthood.
c. NMDA receptor modulation
The NMDA receptors are modulated by various substances including sulfydryl reagents,
polyamines, histamine, protons, ethanol, protein kinases, arachidonic acid, cations and
numerous organic compound (23). More importantly, channels, irrespective of their
subunit composition, are inhibited by a voltage dependant Mg2+ block. GluN2A
containing receptors are modulated and inhibited by Zn2+ ions while GluN2B receptors
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are allosterically inhibited by phenolethanolamine derivatives like ifenprodil (40-43). The
allosteric modulators typically bind to the amino terminal region of the receptors (44).
d. NMDA receptor subunit topology
The different subunits of NMDA receptors share a similar topology to the other nonNMDA receptors. Each subunit is composed of anywhere from 900- 1500 amino acids
and is a single gene product. The domain organization of the single subunit is shown in
Figure 9. The extracellular region is composed of an Amino Terminal Domain (ATD)
(where allosteric modulators bind) and an Agonist binding domain (ABD) (glycine and
glutamate binding modules) (12, 13). The 350 amino acid ATD bears resemblance to
the bacterial LIVBP (Leucine/ Iso-leucine/ Valine binding protein) and also the mGluR1
(metabotropic Glutamate receptor) glutamate binding subunit (45). The ATD is primarily
involved in organization and also has modulatory effects on the channel (46). However,
NMDA receptors lacking the ATD express have been shown to be functional similarly to
the wild type (43, 47). Below the ATD lies the 280 amino acid ABD where the agonist
glutamate binds in the GluN2 subunit and glycine in the GluN1 subunit. The ATD and
ABD both have clamshell like bi-lobed domains. The ion channel pore consists of three
transmembrane regions M1, M2, M3 and a re-entrant loop M2 which is similar to the Ploop of the voltage gated channels (11). The pore region confers selectivity to the ion
channel and below the channel segments lays the variable length intracellular CTerminal tail. Calmodulin and other proteins have been shown to bind to this region.
e. Crystal structures of the isolated ABD of NMDA receptor
Crystal structures of the ABD of NMDA receptor GluN1 subunit was solved in 2003 by
Eric Gouax and co – workers (12) (Figure 2). Similar to the other non- NMDA receptors,
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the NMDA receptor subunit is also modular and the ABD has been excised, expressed
as a soluble bacterial protein and crystallized in complex with various ligands (13). The
crystal structures of the isolated ABD of the three subtypes of ionotropic glutamate
receptors have provided a first glimpse into the conformational changes accompanying
agonist binding and have given a rudimentary understanding into the mechanism by
which agonists could control activation and eventually the desensitization of ion
channels (48-50). There are more than sixty structures of the AMPA subtype in complex
with a variety of ligands of differing efficacies (7, 51). Based on these structures, a
graded cleft closure hypothesis was developed for activation of the AMPA subtype
where the cleft closure correlated to the extent to of activation or in other words efficacy
of the agonist (52-54). Hence it has been proposed that this is the coupling mechanism
by which the agonist controls the gate (Figure 3). However for the NMDA subtype, the
least studied among the GluR subtypes, such a wealth of crystallographic data is not
available. The structures of the ABD of the GluN1 subunit bound to full agonist glycine
and partial agonists such as D-cycloserine and ACPC showed no significant differences
in the extent of cleft closure (Figure 2) (12, 13). Based on these structures it has been
hypothesized that the NMDA receptors could follow a two state model, where the cleft
exists in either an open or closed form. In addition, at present there is only one structure
available for the isolated ABD of the GluN2A subunit, it is of a dimer of GluN1-GluN2A
bound to their respective agonists- glycine and glutamate (13) (Figure 2). The glutamate
bound GluN2A subunit cleft is closed. Therefore, it is still not known if the GluN2 subunit
exhibits a graded cleft closure as seen for the AMPA and kainate subtypes.
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Figure 2 Crystal structures of GluN1 ABD in complex with Glycine and D-cyclo serine
(DCS) (12, 14). Glycine and glutamate bound crystal structure of GluN1-GluN2A ABD
dimer (13).
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Figure 3 Cleft closure versus activation in AMPA receptors.
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f. Significance
Alzheimer’s disease (AD) is the most common cause of dementia and is estimated to be
the fourth largest cause of death for people over 65 years of age in the US.
Excitotoxicity or overstimulation of ionotropic glutamate receptors (iGluRs) is one of the
key causes linked to the onset and progression of AD(55). Of particular interest is the
highly Ca2+ permeable N-methyl-D–aspartate (NMDA) receptor, a subtype of iGluR
whose excessive uncontrolled firing has been implicated in cognitive dysfunction,
memory loss and other psychiatric symptoms (Figure 4). Hence major focus has been
given on the development of antagonists or drugs that specifically target these
receptors, thereby preventing neuronal injury and cell death. Given the undeniable
importance of these receptors in mediating critical physiological processes, there is an
ever-increasing need to devise effective strategies to judiciously manipulate their
function in disease states (56). However, there are currently only four FDA approved
medications to treat the cognitive degeneration manifested in AD patients. Memantine,
an antagonist that blocks NMDA receptors, is one of those drugs and is moderately
efficient in treating moderate to severe forms of AD. The major hurdle towards the
development of target drugs has been the lack of a clear understanding of the molecular
mechanism by which agonists/ligands mediate activation of NMDA receptors. In this
dissertation, I will address this critical gap by employing an LRET (luminescence
resonance energy transfer) based assay and relate the newly observed large scale
conformational changes to documented functional properties.
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Figure 4 The binding of ligands induces activation of NMDA receptors resulting in
calcium entry into the cell. Alzheimer’s disease (AD) results from uncontrolled activation
of these receptors.
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Chapter 2 - Fluorescence Resonance Energy Transfer (FRET)
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I. Fluorescent Resonance Energy Transfer (FRET)
Described over 50 years ago, Fluorescence Resonance Energy Transfer (FRET) is a
physical phenomenon that is now widely used in biomedical and drug research studies
(57). FRET is the radiationless, distance-dependent transfer of energy from a donor to
an acceptor molecule (58). It is widely used to investigate molecular interactions due to
its increased sensitivity to distance. Energy is initially absorbed by a donor dye or
chromophore which is then subsequently transferred to an acceptor chromophore. This
transfer of energy leads to a reduction in the donor’s fluorescence intensity and excited
state lifetime, and an increase in the acceptor’s emission intensity. In order for FRET to
occur the following conditions have to be satisfied:

The distance range that typically

can be measured by FRET is around 10-100 Å (59).

There must be an overlap

between the excitation spectrum of the acceptor and the emission spectrum of the
donor moiety (Figure 5). This degree of overlap is often referred to as the spectral
overlap integral (J).

In addition, the transition dipole orientations of the donor and

acceptor must be approximately parallel. The dependence between efficiency of the
process (E) and the distance between donor and acceptor is given by the Förster
equation (Equation 1).


  1  



(1)

Ro is the distance at which energy transfer is 50% and r is the distance between donor
and acceptor. The magnitude of the Ro is contingent on the spectral properties of the
donor and the acceptor dye molecules. FRET is often referred to as a spectroscopic
ruler since any process that affects energy transfer rate can be quantified. The Förster
distance (Ro) given in Equation 2 is dependent on a variety of factors, including the
18

Figure 5 FRET occurs when the emission spectrum of the donor overlaps with the
absorbance spectrum of the acceptor. Figure adapted from Selvin P.R., 1995 (59).
This research was originally published in Journal of Biological Chemistry. Gonzalez, J.,
Rambhadran, A., Du, M., and Jayaraman V. (2008) LRET Investigations of the
Conformational Changes in the Ligand Binding Domain of a Functional AMPA Receptor.
Biochemistry. 47(38):10027-32. Copyright the American Society for Biochemistry and
Molecular Biology.

19

20

quantum yield of the donor(ΦD), the refractive index of the solution (n), the dipole
angular orientation of each molecule (k2), and the spectral overlap integral of the donor
and acceptor (J).
R06 =

8.785 *10 −5 * κ 2 * φ D * J
n4

∑ F (λ )* ε (λ )* λ
J=
∑ F (λ )
D

i

A

i

4
i

i

D

i

i

In most of the cases the donor and acceptor molecules are different, and FRET is
detected by appearance of fluorescence of the acceptor or by the quenching of donor
fluorescence. The donor probe is usually a fluorescent molecule, but on the other hand,
a luminescent probe behaves as a fluorescent molecule in regards to its emission.
When excited, electrons jump from the ground state (So) to a higher vibrational level.
Within picoseconds, these electrons decay to the lowest vibrational levels (S1) and
eventually decay (nanosecond time scale) back to the ground state. In this process, a
photon of light is emitted (57). When resonance energy transfer occurs, the photon is
not emitted; instead energy is transferred to the acceptor molecule, whose electrons in
turn get excited similar in manner to the donor molecule. The acceptor subsequently
returns to the ground state upon emitting a photon (Figure 6).
II. Luminescence Resonance Energy Transfer (LRET)
A slightly modified version of FRET is the LRET (Luminescence Resonance Energy
Transfer) technique where the donor is luminescent (60, 61). A luminescent lanthanide
donor like terbium chelate is employed and upon excitation it transfers energy to a
fluorescent acceptor molecule for example, ATTO465-maleimide, Fluorescein.
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Figure 6 Jablonski diagram. Adapted from Lakowicz et al. 1983 (57).
This research was originally published in Journal of Biological Chemistry. Gonzalez, J.,
Rambhadran, A., Du, M., and Jayaraman V. (2008) LRET Investigations of the
Conformational Changes in the Ligand Binding Domain of a Functional AMPA Receptor.
Biochemistry. 47(38):10027-32. Copyright the American Society for Biochemistry and
Molecular Biology.
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LRET typically has a number of advantages to the traditional FRET method, greater
distance range; temporal resolution of signals; a decrease in error in distance
measurements; and finally multiple distances can be determined for a single system
(62, 63).
These advantages are attributed to the inherent properties of terbium chelate, the donor
used in LRET studies. Terbium chelate is isotropic, which greatly reduces the error
associated with the FRET and has a high quantum yield. The four distinct emission
peaks allow spectral separation of donor and acceptor fluorescence (Figure 7). This
distinction offers the advantage of being able to employ a variety of acceptor pairs to
give a variety of R0 values.
The long lifetime of terbium chelate in the microsecond to millisecond timescale allows
for the temporal separation of the acceptor only (which typically has a nanosecond
lifetime), donor only, and LRET signal (which usually is in the microsecond scale). The
donor only sample does not contribute to the LRET signal since LRET is measured at
the wavelength of the acceptor; this measurement is referred to as sensitized emission.
The sensitized emission is due to the acceptor gaining fluorescence from the donor.
Based on lifetimes, the following equation (Equation 4) is used to calculate distances:
1/ 6

 τ DA 

R = R0 
 τ D − τ DA 

Where, τD is the time constant for donor fluorescence decay in the absence of the
acceptor and τDA is the sensitized emission of the acceptor due to the energy transfer
from the donor.
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III. LRET Instrumentation
Fluorescence Spectroscopy. A cuvette based fluorescence lifetime spectrometer
QuantaMaster Model QM3-SS (Photon Technology International, NJ) is used for
performing fluorescence measurements. The excitation source is a high power pulsed
xenon lamp. Additionally, the collected emitted light is passed through a monochromator
onto a detector. Using a Peltier TE temperature controller, the sample is held at a
constant 15°C temperature. Fluorescan software was used to collect data (Photon
Technology International, NJ), and Origin 4.0 software is used to analyze the data
(OriginLab Corp., MA) (63). Data from three to four sets of data are averaged and fitted
to obtain the lifetimes. Each individual data set is examined to ensure similar trends
were maintained. The donor only lifetimes were collected at 545 nm for Terbium
chelate, and the sensitized emission of acceptor were measured at 510 nm for ATTO
465 and 515 nm for Fluorescein in order to obtain the LRET lifetimes. The fluorescence
decay was fitted to a function that is a sum of discrete exponentials and the goodness of
the exponential fit was determined from the random residual distribution with a chisquare value being close to unity.
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Figure 7 Excitation and emission spectrum of Terbium chelate. Adapted from Invitrogen
(Lantha Screen Thiol Reactive Terbium Chelate) product webpage.
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Chapter 3—Two- Electrode Voltage Clamp (TEVC)
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I. Expression system – Xenopus Laevis system
The Xenopus oocyte was initially used to express functional ion channels and
receptors in 1982 and since then has become an ideal system to express and to
characterize ion channels (64). Biophysical characterizations of ion channels using
Xenopus oocytes is very simple using TEVC recordings as oocytes are large (around 1
mm in diameter). Injections of either DNA or RNA of the protein of interest are possible
with oocytes. Expression can be modulated by altering the amount of DNA/RNA that is
injected and the oocytes are capable of translating these nucleotides to protein (65).
Proteins are trafficked and sent to their respective destination, for example, plasma
membrane protein is trafficked to the plasma membrane. Although it depends on the
amount and type of receptor, typically 25-50 ng of RNA is injected into each oocyte.
Also, oocytes have the machinery to allow for post translational modifications of protein.
Xenopus laevis oocytes are unfertilized eggs from the African clawed frog, and supply is
easy to maintain,because frogs produces oocytes throughout the year. After surgical
extraction and enzyme treatment, oocytes can be stored in saline solutions with
antibiotics for over 7 days.
However, the Xenopus laevis oocyte expression system has several disadvantages.
There are batch to batch variations in expression levels and the quality of oocytes. It is
a transient expression system where expression of endogenous protein could interfere
with the injected protein expression. Several important factors need to be kept in mind
before selecting oocytes as an expression system: the amount of RNA to be injected,
expression time and pattern, and finally the number of oocytes based on the level of
expression.
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The most critical step in the utilization of oocytes for LRET experiments was the
optimization of the expression system by employing a pre- blocking reagent and
introducing a protease cleavage site to account for background labeling (66). For the
LRET measurements, maleimide derivatives of dyes are used as donor and acceptor
pairs to label the cysteine mutations introduced in the protein of interest. Thus, there
was the problem of background inherent cysteines that inadvertently got labeled and
hence contributed to the LRET signal. In order to avoid this issue, a pre- blocking step
was introduced (a schematic of the process is shown in Figure 8). A maleimide
derivative was used to block inherent cysteines prior to receptor expression (details in
the appendix).
II.Two Electrode Voltage Clamp (TEVC)
The usefulness of the voltage clamp stems primarily from the fact that it allows the
separation of membrane ionic and capacitative currents. Secondly, it is much easier to
obtain information about channel behavior using currents measured from an area of
membrane with a uniform, controlled voltage, than when the voltage is changing freely
with time and between different regions of membrane. The method was initially
developed by Cole in 1949 and later by Hodgkin et al. in 1952 for use with the squid
giant axon (67). Since then, many variants of the technique have evolved and voltage
clamp analysis has been extended to a wide range of tissues.
The membrane potential (V) is measured in volts and this is caused by the charge
separation across the membrane. Current (I) is generated by the movement of ions
across the membrane. Two electrodes, namely the current and voltage electrodes are
inserted into the oocyte. The voltage electrode measures the membrane potential
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Figure 8 A schematic of the expression system in oocytes used for LRET experiments
in the NMDA receptors.
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relative to the ground, while the current electrode is injecting current into the oocyte.
The holding voltage is set to -60 mV and this is achieved by the voltage clamp using a
negative feedback mechanism .Whenever ligand is added, the channel opens and ions
flow through causing a deviation from the command voltage. The amplifier detects the
difference and sends out an output signal to the current electrode. This detection and
resulting signal help to maintain the holding potential. The signal equal and opposite to
the current is produced and this can be measured as the current from the oocyte.
TEVC experiments were used in order to validate the functionality of the NMDA receptor
and derivative mutants. The cysteine mutants used for the LRET experiments were
tested for their functional properties relative to the wild type in order to establish that the
mutations did not alter the biophysical properties or expression of the receptor.
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Chapter 4 — Part I: LRET investigations to determine subunit arrangement in
NMDA (N- Methyl- D- Aspartate) receptors
This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2010. Subunit arrangement in N-Methyl-D-aspartate
(NMDA) receptors. Journal of Biological Chemistry 285(20):15296-301. Copyright the
American Society for Biochemistry and Molecular Biology.
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I. Architecture of N-Methyl-D-aspartate (NMDA) receptors
NMDA receptors are distinctly different from non-NMDA receptors such as AMPA
and kainate receptors which can form functional homotetrameric channels activated
solely by glutamate (23). The NMDA subtype is obligate heterotetramers comprised of
glycine-binding GluN1 or GluN3 subunits and glutamate-binding GluN2 subunits.
Depending on the cell and the developmental stage, typically one of the four GluN2
subunits (A–D) combines with a splice variant of the GluN1 subunit, yielding receptors
with distinct deactivation kinetics (23). The topology of the NMDA receptor is similar to
the other non- NMDA subtypes, typically the GluN1, GluN2 and GluN3, have a similar
membrane topological structure, with three transmembrane domains plus a pore-loop
sequence that lines the channel (Figure 9).
The extracellular portion of the receptor consists of two domains: an N-terminal
domain (ATD) and the agonist binding domain (ABD). The ATD domain binds
modulatory ligands like Zinc, Ifenprodil etc. but is not essential for the basic function of
agonist induced channel activation and desensitization. Laube and coworkers have
demonstrated that the NMDA receptors are fully functional in the absence of ATD and
therefore in my proposed work to identify the stoichiometry and arrangement of the
NMDA receptors I have used a modified receptor lacking the ATD that still retain the
other functional components (24, 47).
While there is a structure of the full length for AMPA receptor in complex with an
antagonist, there is currently no structural data available for the full length NMDA
receptor (11).
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Figure 9 Schematic of NMDA receptor topology.

(A) NMDA receptor tetramer

consisting of glycine binding NR1 subunit and glutamate binding NR2A subunit. (B) A
single subunit contains an extracellular N-terminal domain, an extracellular ligand
binding domain, three transmembrane segments and a re-entrant loop that form the
transmembrane domain, and a intracellular C-terminus.
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There is only one structure of the NMDA receptor GluN1-GluN2A ABD in complex with
each other and this structure suggests that one of each subunit forms the dimer (13).
However there is no knowledge of how the dimer assembles to form the tetramer.
Additionally, even for the structure of a dimer, it should be noted that these structures
were of the isolated ABD lacking the functional component of the receptor; the
transmembrane segments. Hence it is still possible that in the tetramer this structure
may not reflect the actual arrangement. Given the fact that several laboratories have
tried to express the full length NMDA receptor and have not been successful, the
proposed LRET experiments provide the best alternative, while limited in terms of not
being able to provide the complete structure, to be able to provide distance constraints
that will in turn be able to provide insight into the arrangement of subunits in this
important class of glutamate receptors. In this chapter, the LRET technique was used in
order to study the specific arrangement of subunits in a functional NMDA receptor in a
physiologically relevant state.
II. Establishing the subunit arrangement of NMDA receptor
LRET is an excellent tool to probe the specific arrangement in which the subunits
assemble, the advantage lies in the ability to attach donor and acceptor probes at
strategic locations in the protein and by using the right pair of fluorophores to allow us to
distinguish the different arrangements of the receptor (63)(Figure 10). Hence for
studying the subunit arrangement of the NMDA receptor, I used modified GluN1 and
GluN2A subunits of the NMDA receptor lacking the N-terminal domain. To achieve this,
residues numbered 5-357 of the mature peptide were deleted for the GluN1 subunit
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Figure 10 Possible subunit arrangements in the NMDA heteromeric receptor - where
NR1’s are either arranged in a back to back manner, across from each other or the
NR1s could be arranged sideways, adjacent to each other NMDA receptors are thought
to be a dimer of dimers. Crystal structures of the isolated ligand binding domain suggest
that one NR1 and one NR2 subunit form the dimer.
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while for GluN2A residues 1-385 were deleted. Additionally, to ensure proper
expression of the GluN2A subunit, a modified influenza hemagglutinin (HA) tag replaced
the original signal peptide sequence (43, 47). These modifications were similar to the
kind done by Laube et.al. and the expression of the modified receptor subunits were
further verified by electrophysiological recordings and compared to the response from
wild type receptors (47). The N-terminal domain lacking GluN1, and GluN2A subunits
(∆GluN1, ∆GluN2A) were further altered to eliminate any single non-disulphide bonded
accessible cysteines. This mutagenesis approach was critical for the success of the
LRET experiments since the fluorophores used were maleimide derivatives, hence to
prevent background non- specific labeling it was essential to eliminate inherent nondisulphide bonded accessible cysteine. The following mutants were made; C459 in
GluN1 and C399 in GluN1, C460 in GluN2A were mutated to serine. The cysteine free
modified subunits (∆GluN1* and ∆GluN2A*) served as background constructs and were
used for LRET investigations by introducing either cysteines and or histidine tags that
acted as donor and or acceptor sites.
In order to determine the distance between GluN1 subunits a cysteine followed by a
thrombin cleavage site (C-Th) was introduced at the N-terminus of the ABD of GluN1
(Residue 396). Similarly residue 404 was chosen for the GluN2A subunit measurement
(Figure 11). The thrombin cleavage site allowed us to selectively cleave the donor or
acceptor fluorophore tagged to these sites. LRET lifetime is recorded before and after
thrombin digestion. The final specific LRET signal was obtained upon subtracting the
background non- specific lifetime. This technique was developed by the Jayaraman lab
and has enabled us to overcome the background non- specific signal and thereby
41

Figure 11 Possible arrangements of NR1-NR2A receptors agonist binding domains 1
and 2 based on full length AMPA receptor crystal structure. The position of the NR1
subunit on the AMPA receptor structure is colored in red for Domain 1 and in pink for
Domain 2. The position of NR2A subunit on the AMPA receptor structure is colored in
green for Domain 1 and pale green for Domain 2. Homologous sites tagged in the
modified ∆NR1* and ∆NR2A* subunits for LRET measurements are highlighted.
This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2010. Subunit arrangement in N-Methyl-D-aspartate
(NMDA) receptors. Journal of Biological Chemistry 285(20):15296-301. Copyright the
American Society for Biochemistry and Molecular Biology.
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allowed us to work with a non- purified system in a physiological state with minimum
manipulation (62)(Figure 12 ).
Distances

within

GluN1

and

within

GluN2A

subunits:

The

∆GluN1*T396C-

Th/∆GluN1*396Histag:∆GluN2A* labeled with terbium: Ni-(NTA)2-Cy3 chelate serving
as donor: acceptor pair was used to measure the distance between residue 396 on one
GluN1 subunit with respect to the same residue on the second GluN1 subunit (Figure
11) (68). This combination of receptors did not give any significant LRET signal
suggesting that the distance between the residue 396 on one GluN1 subunit with
respect to the same residue on the second GluN1 subunit is longer than that
measurable by the terbium respective donor: acceptor pair. The R0 for this pair is 65 Å,
therefore for distances >100 Å the efficiency of transfer decreases to around 6% (Figure
13). Hence it can be concluded that the distance between residues 396 on the two
GluN1 subunits is > 100 Å. In a similar manner, to measure the distance between
residue 404 on one GluN2A subunit and the same residue on the second GluN2A
subunit, ∆GluN1*:∆GluN2A*N404Histag/ ∆NR2A*N404C-Th construct was used and
labeled with terbium: Ni-(NTA)2-Cy3 chelate. The LRET lifetime for this mutant (Figure
14) could be well represented by a single exponential decay, and the corresponding
distance obtained from this lifetime was 60 Å. In order to measure distances between
GluN1 and GluN2A subunits, the construct ∆GluN1*396Histag: ∆GluN2A*N404C-Th
receptor tagged with terbium:

Ni-(NTA)2-Cy3 chelate was used. The LRET lifetime

measured between residue 396 on GluN1 and residue 404 on GluN2A required a two
exponential fit (Figure 11). The two lifetimes correspond to two distances between the
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Figure 12 Strategy for control experiments in LRET investigations
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Figure 13 A plot of efficiency of FRET vs distance between fluorophores is shown for
a typical donor: acceptor pair. In this case Terbium chelate: Ni-(NTA)2-Cy3 was used.
This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2010. Subunit arrangement in N-Methyl-D-aspartate
(NMDA) receptors. Journal of Biological Chemistry 285(20):15296-301. Copyright the
American Society for Biochemistry and Molecular Biology.
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Figure 14

(A) LRET lifetimes for ∆NR1*T396Histag/∆NR1*T396C-Th:∆NR2A* labeled

with Terbium-chelate:(Ni-NTA)2Cy3

as measured by the sensitized emission of

acceptor at 575 nm in the presence of saturating concentrations of agonists. No LRET
signal was observed. (B) LRET lifetimes for ∆NR1*:∆NR2A* N404Histag/∆NR2A*
N404C-Th labeled with Terbium-chelate:(Ni-NTA)2Cy3 as measured by the sensitized
emission of acceptor at 575 nm with saturating concentrations of agonists. (C) LRET
lifetimes measured at 575 nm for ∆NR1*T396Histag:∆NR2A* N404C-Th labeled with
Terbium chelate:(Ni-NTA)2Cy3 under saturating concentrations of agonists.(D) LRET
lifetimes measured at 515 nm for ∆NR1*Th-Q525C-Th:∆NR2A* labeled with Terbiumchelate:Fluorescein at saturating concentrations of agonists.

For all mutants, the

sensitized lifetime shown is the difference between the lifetimes obtained before and
after thrombin digestion.

The residuals for the lifetime fits are shown below each

measurement with the Y-axis in linear scale.
This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2010. Subunit arrangement in N-Methyl-D-aspartate
(NMDA) receptors. Journal of Biological Chemistry 285(20):15296-301. Copyright the
American Society for Biochemistry and Molecular Biology.
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GluN1 and GluN2A subunits. The LRET based distances obtained for the above
mentioned constructs are compared to the distances for equivalent residues on the
AMPA receptor full length structure for the three possible configurations in Table 1. The
comparison of distances yields a final configuration that best matches Figure 15.
In order to further confirm that the NMDA receptors assembled in the configuration
shown in Figure 15, we also measured the distance between residues 525 on one
GluN1 subunit with respect to the same residue on the second GluN1 subunit. This
particular residue was chosen because the distance changes significantly between the
three possible configurations (Table 2) and therefore can be differentiated in the LRET
studies. Hence for measuring this distance, ∆GluN1*Th-Q525C-Th:∆GluN2A* construct
was used and labeled with a 1:1 ratio of terbium chelate and fluorescein. The LRET
lifetime for this construct could be well represented using a single exponential decay
suggesting primarily a single configuration for the NMDA receptor (Figure 14). More
importantly, the LRET based distance of 51 Å is closest and similar to the distance of 49
Å seen in the final proposed configuration shown in Figure 10, thus confirming that the
NMDA receptors are primarily in the configuration shown in Figure 11 A. The results
from the LRET studies are consistent with the crosslinking experiments performed by
Eric Gouaux et.al. (Figure 20) where it has been shown that residue E699 on GluN1
subunits cross links with the corresponding residue E699 on the second GluN1 subunit
(configuration 8A), however no crosslinking was observed between K641 or R645 and
N675/E699 (in GluN1) and K641 or R645 (in GluN2) as would be expected for
configurations in Figure 11B and Figure 11C (11) .
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Figure 15

Sites that were tagged in the modified ∆NR1* and ∆NR2A* subunit for

LRET measurements within the dimer are highlighted in the crystal structure of NR1NR2A dimer (13).
This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2010. Subunit arrangement in N-Methyl-D-aspartate
(NMDA) receptors. Journal of Biological Chemistry 285(20):15296-301. Copyright the
American Society for Biochemistry and Molecular Biology.
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Figure 16

(A) LRET lifetimes for ∆NR1*775tetrahistag:∆NR2A*S519C labeled with

Terbium-chelate before (donor) and after addition of Ni2+. (B) LRET lifetimes for
∆NR1*525tetrahistag:∆NR2A*L777C labeled with Terbium-chelate before (donor) and
after addition of Ni2+. The residuals for the above lifetime fits are shown below each
measurement, and the Y-axis is in linear scale.
This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2010. Subunit arrangement in N-Methyl-D-aspartate
(NMDA) receptors. Journal of Biological Chemistry 285(20):15296-301. Copyright the
American Society for Biochemistry and Molecular Biology.
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Table 1 The fluorescence lifetimes and distances for ∆NR1*:∆NR2A* receptors.
This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2010. Subunit arrangement in N-Methyl-D-aspartate
(NMDA) receptors. Journal of Biological Chemistry 285(20):15296-301. Copyright the
American Society for Biochemistry and Molecular Biology.
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Protein

Donor:Acceptor
fluorophore pair

∆NR1*T396Histag/
∆NR1*T396C-Th:

Donor
lifetime
(µs)

Sensitized
emission
lifetime
(µs)

Distance
(Ǻ)

Apo

Apo
state

Sensitized
emission
lifetime
(µs)

Distance
(Ǻ)

Desensitiz
ed

Desensit
ized
state

1900±1

No LRET

>100

No LRET

>100

∆NR2A*

Terbium
chelate:(NiNTA)2Cy3

∆NR1*:∆NR2A*N40
4Histag/
∆NR2A*N404C-Th

Terbium
chelate:(NiNTA)2Cy3

1750±21

634±41

59.1±0.8

672±12

60.1±0.3

∆NR1*T396Histag:
∆NR2A* N404C-Th

Terbium
chelate:(NiNTA)2Cy3

1904±5

1203±23/

71.1±0.5

1254±36

72.5±0.8

304±14

49.2±0.4

318±24

49.7±0.6

∆NR1*Th-Q525CTh:∆NR2A*

Terbium
chelate:Fluoresc
ein

1606±8

1010±28

49.1±0.5

1089±12

51±0.3

∆NR1*525tetrahista
g:∆NR2A*L777C

Terbium
chelate:Ni 2+

1754±5

1088±8

13.0±0.0
5

1155±42

13.3±0.2

∆NR1*775tetrahista
g:∆NR2A*S519C

Terbium chelate:
Ni 2+

1681±10

1290±61

14.6±0.4

1330±50

14.9±0.4

∆NR1*T396C-Th,
A715C: ∆NR2A*

Terbium
chelate:ATTO46
5

1704±18

734±33

34.4±0.3

790±16

35.1±0.2
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III. Mechanism of desensitization of NMDA receptor based on distance within the
dimer interface
It is hypothesized that when a ligand like glutamate binds to the extracellular ABD, it
causes the cleft to close, which in turn pulls apart the transmembrane segments
causing the channel to open. Upon prolonged exposure to the ligand, the receptor
eventually desensitizes; the channel closes owing to the stress on the transmembrane
segments caused by the decoupling of the dimer interface (48). This hypothesis for
desensitization is based on previous structural data obtained from the isolated ABD
crystal structures of AMPA receptors that showed cyclothiazide, an allosteric modulator,
and mutations in the dimer interface, like L483Y, that stabilize the dimer interface block
desensitization (48). However, currently there is no structural information regarding the
mechanism of desensitization of NMDA receptors. Here, we have used LRET distances
of residues within the GluN1-GluN2A dimer interface to extrapolate the mechanism of
desensitization of NMDA receptors.
Two sets of residues expected to be in close proximity in the dimer interface
based on the X-ray structures of GluN1-GluN2A dimer were chosen for the LRET
studies: The first set was residues 525 on GluN1 and 777 on GluN2A and the second
pair was residues, 775 on GluN1 and 519 on GluN2A (Figure 15). In order to precisely
measure the distance within the dimer and not across the dimer a cysteine mutation
was introduced on one subunit while a tetrahistidine tag (HHHH) was introduced on the
second subunit. Maleimide derivatives of terbium chelate served as the donor and Ni2+
ion (R0 is 12 Å) acted as the acceptor. The short R0 of 12 Å ensured that distances only
within the dimer were measured and there was no transfer from the residues across the
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dimer interface. In addition, the short R0 also ensures that the non-specific labeling of
cysteine residues far from the histidine tag does not contribute towards the LRET signal
being measured. Therefore when short distances were measured it obviated the need
to introduce a thrombin cleavage site to account for background signal. The LRET
lifetimes for ∆GluN1*525tetrahistag: ∆GluN2A*L777C and ∆GluN1*775tetrahistag:
∆GluN2A*S519C (Figure 17) could be well represented by a single exponential fit and
the respective distances are shown in Table2 and compared to the distances from the
crystal structure. Saturating concentrations of the ligands glutamate and glycine were
employed to make sure that the distances obtained primarily represent the desensitized
state of the receptor. While the crystal structures of the isolated ABD of the GluN1GluN2A dimer lack the transmembrane portion, the functional component of the
receptor that drives the formation of the desensitized state and therefore most likely
represents the structure of the dimer in the open channel form of the protein and not the
desensitized form (13). The longer LRET distances in the desensitized state of the
NMDA receptor relative to the distances expected for the open channel form suggests
that there is a decoupling of the dimer interface in the desensitized state of the receptor.
In order to confirm the accuracy of such a direct comparison of LRET distances to Xray structures, we measured the distance within a given subunit of the receptor. For this
purpose, ∆GluN1*T396C-Th, A715C: ∆GluN2A* was used; this construct allowed us to
measure the distance between residues 396 and 715 within GluN1 subunit. This
construct was labeled with terbium chelate and ATTO 465 as donor and acceptor,
respectively, for LRET measurements. A single exponential decay well represented the
LRET lifetime and corresponded to a distance of 35.1 Å. This measurement was very
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Table 2 Comparison of distances between desensitized state LRET measurements to
antagonist bound crystal structure of AMPA receptor with other possible configurations.
This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2010. Subunit arrangement in N-Methyl-D-aspartate
(NMDA) receptors. Journal of Biological Chemistry 285(20):15296-301. Copyright the
American Society for Biochemistry and Molecular Biology.
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AMPA receptor (PDB-3KG2)

NMDA/Homologous
AMPA receptor

NR1-396 to NR2A-404/
AMPA-393 to AMPA-393
NR1-396 to NR1-396/
AMPA-393 to AMPA-393
NR2A-404 to NR2A-404/
AMPA-393 to AMPA-393
NR1-525 to NR1-525/
AMPA-487 to AMPA-487

Distance based
on

Distance based
on

Distance based
on

configuration

configuration

configuration

A (Figure1) (Ǻ)

B(Figure1) (Ǻ)

C(Figure1) (Ǻ)

72.5

67

67

56,102

>100

101

56

72

60

56

102

67

51

49

82

65

Distance
based on
LRET (Ǻ)
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similar to the observed distance of 34.3 Å in the crystal structure (Figure 17) of GluN1
subunit (14). This particular pair of residues was chosen keeping in mind that the
efficiency of transfer from the second GluN1 subunit is expected to be only 0.2% for
transfer between residues 396 and 396 while for transfer between residues 715-715 the
transfer efficiency is 3.3% when terbium chelate and ATTO 465 are used as donor and
acceptor, respectively. Therefore, these mutations do not interfere and contribute to the
measured LRET signal, thus allowing us to selectively measure distance within a given
subunit of GluN1. Table 3 shows a comparison of distances between the desensitized
LRET measurements to the changes in distances observed for homologous residues in
the desensitized like crystal structure of S729C mutant and the cyclothiazide (CTZ)
bound open channel structure of the AMPA receptor (48). The distance changes
between the desensitized and open channel form across the dimer for the NMDA
receptors are found to be similar to AMPA receptors. This observation confirms that the
dimer interface in the NMDA receptors is decoupled and provides evidence for the first
time that the mechanism for desensitization in the NMDA receptors is similar to that
observed in the AMPA receptors (48).
IV. Results and Discussion
Using the LRET distances determined as described above between GluN1, GluN2A and
between GluN1 and GluN2A subunits, we have established the specific unique
configuration in which the NMDA receptor subunits assemble to form the functional
tetramer. The results show that the dimer of dimers structure is formed with the GluN1
subunits assembling diagonal to each other. The measured LRET distances are
consistent with the NMDA structure predicted by Eric Gouaux based on crosslinking
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Table 3 Comparison of changes in distances between desensitized and open channel
states of NMDA and AMPA receptors.
This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2010. Subunit arrangement in N-Methyl-D-aspartate
(NMDA) receptors. Journal of Biological Chemistry 285(20):15296-301. Copyright the
American Society for Biochemistry and Molecular Biology.
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NMDA receptor
Protein

NR1-396 to
NR2A-404
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(Ǻ) (B)
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Distance
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Protein

experiments and also based on the structure of the AMPA receptor (GluA2) full length
structure. In addition, the LRET distances measured between GluN1 and distances
observed are in line with the decoupling of the dimer interface, resembling the
desensitized state of the receptor. Since the isolated ABD crystallizes in the open
channel state of the receptor, the longer LRET lifetime previously reported for the AMPA
subtype of the glutamate receptors suggest that the mechanism for desensitization in
the two subtypes of the glutamate receptor are very similar.
a. Receptor characterization by electrophysiology The modified NMDA receptor
mutant proteins were expressed by injecting Xenopus oocytes with RNA encoding the
respective modified GluN1:GluN2A subunits in a 1:2 ratio. Upon injection, the oocytes
were incubated at 12 °C to allow them to recover from injection and also to minimize
surface expression of the receptor. After 2 days, the oocytes are pre-blocked with βmaleimidopropionic acid for one hour at 18°C to block inherent cysteines from reacting
non- specifically to the maleimide fluorophores used for LRET studies. This preblocking procedure was initially established in the potassium channels where blocking
inherent cysteines of the oocyte increased the specificity of labeling of the receptor. The
blocked oocytes continued at 18 °C for 24 hours to allow expression of the receptor.
After 24 hours, the oocytes are labeled with maliemide derivatives of respective
fluorophores for one hour. The excess unreacted fluorophore is then washed away with
buffer. The fluorophore pairs are chosen based on the distances to be measured and
the Ro of the fluorophores. A sample for a pair with an R0 value of 65 Å is shown in
(Figure 13).
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Figure 17 LRET lifetimes for ∆NR1*T396C-Th, A715C:∆NR2A*labeled with Terbiumchelate : ATTO 465 as measured by the sensitized emission of acceptor at 510 nm
under saturating concentrations of agonists. The donor: acceptor lifetime shown here is
the difference between the lifetimes obtained before and after thrombin digestion. The
residuals are shown below the lifetime measurement, and the Y-axis is in linear scale.
This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2010. Subunit arrangement in N-Methyl-D-aspartate
(NMDA) receptors. Journal of Biological Chemistry 285(20):15296-301. Copyright the
American Society for Biochemistry and Molecular Biology.
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R0 value for the following donor: acceptor pairs –Terbium: Ni -(NTA)2-Cy3 chelate is 65
Å, Terbium chelate: Fluorescein
Terbium

chelate:Ni2+ is

12

Å.

is 45 Å, Terbium chelate:ATTO465 is 36 Å and
The

labeled

oocytes

are

then

used

for

electrophysiological recordings, while for the LRET studies membrane preparations of
the oocytes are used. Typically, the oocytes are lysed and solubilized in detergent like
Triton X-100 (see Appendix for protocol on Membrane Preparation. (Ni-NTA)2Cy3, is
added to the membrane preparations for LRET investigations at a final concentration of
1µM when it is used as acceptor fluorophore.
Two methodologies were used to establish the functionality of the modified NMDA
receptor used for LRET studies: two-electrode voltage clamp (TEVC) and single
channel measurements. Membrane fractions from oocytes expressing the modified
receptor were used for the single channel recordings. These experiments were done in
collaboration with Dr. Vishnu Suppiramani at Auburn University. The Po (open channel
probability) for the wild type receptor was similar to the modified NMDA receptor
establishing that the modifications made to the receptor did not affect channel
functioning (Figure 18). For the TEVC measurements each of the modified receptors
used for LRET studies to establish the configuration of the NMDA receptor was used in
order to record the currents elicited and a dose response was created and compared to
the typical wild type response. Currents were recorded using various concentrations of
glutamate as agonist with saturating concentrations of glycine (100µM). Peak currents
were recorded and normalized to currents collected with 100µM glutamate. The dose
response curves for the mutants and wild type are shown in Figure 19. These results
indicate that the mutations
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Figure 18 Single channel recordings from bilayers of membrane preps of modified
NMDA receptors. (Shown here is the N-Terminal deleted NMDA receptor). Single
channel currents of expressed modified NMDA receptors were evoked with glutamate
(2µM) and glycine (1 µM) using the tip-dip bilayer method. (A) Sample trace showing
upward current fluctuations voltage clamped at +60 mV. (B) Amplitude histogram with
an open channel probability of 0.23 and a primary single channel conductance of ~ 25
pS. Calibration 1.5 pA, 100 ms. These results suggest that the membrane preparations
used for the LRET investigations have functional NMDA receptors and the
manipulations for the LRET data collection do not have a significant effect on the
receptor function.
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Figure 19 Dose response curves showing maximum current as a function of glutamate
concentration for the ∆ NR1*: ∆ NR2* and mutant NMDA receptors labeled with
donor:acceptor fluorescent tags using two electrode voltage clamp measurements. All
currents were recorded in the presence of saturating concentrations of glycine (100
µM). Currents were normalized to reading taken with 100 µM glutamate.
This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2010. Subunit arrangement in N-Methyl-D-aspartate
(NMDA) receptors. Journal of Biological Chemistry 285(20):15296-301. Copyright the
American Society for Biochemistry and Molecular Biology.
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and fluorophores introduced for the LRET investigation do not perturb the functionality
of the receptor.
b. Validation of the results based on comparison to full length AMPA structure and cross
linking investigations
The LRET based configuration obtained was similar to the specific tertrameric
arrangement predicted for the ABD of GluN1-GluN2A using cysteine cross- linking
studies. Specifically it was shown that residues N 675 and E699 of GluN1 subunits
spontaneously formed disulphide bonds when mutated to cysteines (Figure 20) (11).
This finding along with the structure of the full length GluA2 subunit of AMPA receptor is
in close agreement with the arrangement proposed by using LRET studies.
V. Future Experiments
While the configuration of the NMDA receptor subunits at the level of ABD has been
established, the arrangement with respect to the ATD is yet to be determined.
Determination of this arrangement is critical especially for the NMDA subtype since this
domain has been shown to modulate the properties of the channel. The current
hypothesis based on biochemical and functional investigations is that allosteric
inhibitors such as Zn2+ and ifenprodil mediate their inhibitory mechanism by inducing a
cleft closure conformational change upon binding to the N-terminal domain (40, 42).
Currently, there is just two crystal structures of the ATD of GluN2B subunit, one in
complex with Zn2+ and of the other of GluN1-GluN2B dimer (40, 42). Hence establishing
the configuration of the full length receptor (including the ATD) using LRET will help in
elucidating the mechanism of modulation of the NMDA receptors. Also, this study will
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further confirm the validity of the arrangement established by LRET in the full length
receptor.
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Figure 20 The full length GluA2 subunit crystal structure along with sites that were
chosen for cross linking studies is highlighted. Adapted from Sobolevsky, A.I. et.al.,
2009 (11).
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Chapter 5 — Part II: Probing the conformational changes in the agonist binding
domain that controls receptor activation in NMDA (N- Methyl- D- Aspartate)
receptors
This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2011. Conformational changes in the agonist binding
domain of NMDA receptors. Journal of Biological Chemistry 286(19):16953-7. Copyright
the American Society for Biochemistry and Molecular Biology.
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I. Testing the activation hypothesis
The structures of the ABD of the GluN1 subunit bound to full agonist glycine and partial
agonists such as D-cycloserine, and ACPC showed no significant differences in the
extent of cleft closure (13, 14). Based on these structures it has been hypothesized that
the NMDA receptors could follow a two state model, where the cleft exists in either an
open or closed form. Activation of the channel could be due to a shift in the equilibrium
between these two states. However, this conclusion has not been tested and is based
only on a limited number of structures. Additionally, if there is a shift in the equilibrium
then at least some of the partial agonist bound structures should be in an open state.
But this trend is not observed in any of the structures solved for the various partial
agonists. Additionally, to draw comparisons between the different subtypes of the
glutamate receptor, it is important to compare subunits that bind glutamate and not the
glycine (inherently different from glutamate) binding site of the GluN1 subunit to
glutamate binding sites of the AMPA receptors. At present there is only one structure
available for the isolated ABD of the GluN2A subunit bound to glutamate (13).
Therefore, it is still not known if the GluN2 subunit exhibits a graded cleft closure as
seen for the AMPA and kainate subtypes (69-71). The hypothesis is that in the
tetrameric form of the receptor, the GluN2 subunit that binds the glutamate would
behave in a similar manner to the other glutamate binding subunits of the other
subtypes of receptor with the extent of cleft closure being the primary mechanism by
which the agonist mediates channel activation (70). In this chapter, I present the use of
LRET is used to measure the amount of cleft closure both in the GluN1 and GluN2A
subunits of NMDA receptor using agonist of varying efficacies.
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II. LRET to measure the extent of cleft closure at the ABD of GluN2A subunit of
the NMDA receptor
In order to study the conformational changes at the ABD of GluN2A subunit, wide range
of activations with different agonists was employed and the LRET based cleft closure
conformational changes were correlated to the differences in efficacies of the agonists
using TEVC recordings.
For the LRET experiments, cysteine mutations were introduced at residue 404 located
at the N-terminus in domain 1 and residue 713 present in domain 2 of the ABD of
GluN2A (Figure 21). This pair of residues was chosen based on the previously
established subunit arrangement of the NMDA receptors such that a direct read out of
cleft closure within the dimer can be obtained and measurement of distances across the
dimer was avoided (72). Since maleimide derivative of fluorophores were employed,
background LRET signal was minimized by introducing a Thrombin (Th) cleavage site
adjacent to the cysteine at position 404(N404C-Th). Thus, the LRET specific to the
GluN2A subunit was obtained upon cleavage with thrombin which selectively cleaves
the donor or acceptor fluorophore labeled at that site (62). The LRET lifetime recorded
after thrombin digestion represents the background non- specific signal, this lifetime
was later subtracted from the original LRET signal to get the final specific LRET signal
for the GluN2A*N404C-Th, V713C mutant (Figure 23).
Maleimide derivatives of Terbium chelate and Fluorescein served as donor and
acceptor fluorophores respectively, for the LRET experiments.

Distances were

recorded between residues 404 and 713 under no ligand (apo), antagonist (DLAPV),
partial agonist (Homoquinolinic acid, HQ), and full agonist (Glutamate) bound state for
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Figure 21 Sites that were tagged in the GluN1* and GluN2A* subunit to probe for cleft
closure conformational changes using LRET measurements are highlighted in the
crystal structure of the ABD of GluN1 bound to glycine and GluN2A bound to
glutamate(12-14) .
This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2011. Conformational changes in the agonist binding
domain of NMDA receptors. Journal of Biological Chemistry 286(19):16953-7. Copyright
the American Society for Biochemistry and Molecular Biology.
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Figure 22 Dose response curves showing maximum current as a function of glutamate
concentration for the GluN1*: GluN2A* and mutant NMDA receptors labeled with
donor:acceptor fluorescent tag using two electrode voltage clamp measurements. All
currents were recorded in the presence of saturating concentrations of glycine (100
µM). Currents were normalized to reading taken with 1mM glutamate.
This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2011. Conformational changes in the agonist binding
domain of NMDA receptors. Journal of Biological Chemistry 286(19):16953-7. Copyright
the American Society for Biochemistry and Molecular Biology.
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Figure 23 Cleft closure in the ABD of GluN2A* subunit: (A) Apo (black) and Antagonist
(DLAPV in magenta) bound LRET lifetimes for GluN1*:GluN2A*N404C-Th, V713C
labeled with Terbium chelate: Fluorescein as measured by the sensitized emission of
acceptor at 515 nm. The residuals for the above lifetime fits are shown below each
measurement, and the Y-axis is in linear scale.
(B) LRET lifetimes for GluN1*: GluN2A*N404C-Th, V713C labeled with Terbium
chelate: Fluorescein as measured by the sensitized emission of acceptor at 515 nm
under saturating concentrations of full agonist (Glutamate in black) and partial agonist
(HQ in red). The residuals for the above lifetime fits are shown below each
measurement the Y-axis in linear scale.
This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2011. Conformational changes in the agonist binding
domain of NMDA receptors. Journal of Biological Chemistry 286(19):16953-7. Copyright
the American Society for Biochemistry and Molecular Biology.
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the GluN2A subunit. In all conditions saturating concentrations of agonists were used.
The concentration of the agonists used was determined based on the dose response
curves created using different concentrations of the agonists. Shown is a typical dose
response curve using glutamate as an agonist (Figure 22), while for other agonists, data
from previous literature was used. The final specific LRET lifetimes obtained upon
subtracting the non – specific background thrombin digested lifetime could be well
represented by single lifetime decay for all the ligands. The lifetimes and the
corresponding distances are given in Table 4.
III. LRET to measure the extent of cleft closure at the ABD of GluN1 subunit of the
NMDA receptor
To fully understand the conformational changes accompanying agonist binding to
NMDA receptors it is critical that changes associated with the glycine binding GluN1
subunit of NMDA receptors also be examined. The crystal structures of GluN1 ABD with
agonists of different efficacies have been solved and they indicate that there are no
changes in the amount of cleft closure between agonists of varying activation (12, 14). It
is still unclear whether this lack of correlation between extent of cleft closure and
activation is due to crystallographic limitations and the absence of the functional
transmembrane component of the receptor. Hence, to resolve this enigma, an LRET
based approach similar to the kind described in the previous section for GluN2A
receptors was used. Conformational changes at the ABD of the GluN1 subunit were
measured using agonists of varying activations in the full length NMDA receptor. For
these experiments, residues 396 at the N-terminus in domain 1 and 715 present in
domain 2 of GluN1 subunit were chosen to give a direct cleft closure read out.
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Figure 24 Cleft closure in the ABD of GluN1* subunit: LRET lifetimes for GluN1*T396
C-Th, A715C: GluN2A* labeled with Terbium chelate: ATTO 465 as measured by the
sensitized emission of acceptor at 510 nm under saturating concentrations of full
agonist (Glycine in black) and partial agonists (DCS in green, ACPC in red). The
residuals for the above lifetime fits are shown below each measurement, and the Y-axis
is in linear scale.
This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2011. Conformational changes in the agonist binding
domain of NMDA receptors. Journal of Biological Chemistry 286(19):16953-7. Copyright
the American Society for Biochemistry and Molecular Biology.
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Table 4 The Fluorescence Lifetimes and Distances for GluN1*:GluN2A* Receptors.

This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2011. Conformational changes in the agonist binding
domain of NMDA receptors. Journal of Biological Chemistry 286(19):16953-7. Copyright
the American Society for Biochemistry and Molecular Biology.
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Donor:
Acceptor

Ligated state

Donor lifetime
(µs)

Sensitized
emission
lifetime
(µs)

1680±40

520±44

39.4±0.6

1694±21

498±26

38.9±0.4

390±25

37.1±0.4

1608±8

295±41

35.1±0.8

1681±10

788±22

35.0±0.1

Distance
(Å)

fluorophore
pair
GluN1*:GluN2A*N404C-Th,
V713C

Tb: Fl

GluN1*:GluN2A*N404C-Th,
V713C

Tb: Fl

GluN1*:GluN2A* N404C-Th,
V713C

Tb: Fl

GluN1*:GluN2A* N404C-Th,
V713C

Tb: Fl

GluN1*T396 C-Th,
A715C:GluN2A*

Tb: ATTO
465

GluN1*T396 C-Th,
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Tb: ATTO
465

1aminocycloprop
ane-1-carboxylic
acid (ACPC)

1754±5
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GluN1*T396 C-Th,
A715C:GluN2A*

Tb: ATTO
465

D- cycloserine
(DCS)
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34.8±0.1

Apo
Antagonist
(DLAPV)
Homoquinolinic
acid (HQ)

Glutamate

Glycine
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1628±12

This mutant GluN1*T396C-Th, A715C: GluN2A* was expressed in Xenopus oocytes
and labeled using maleimide derivatives of Terbium chelate: ATTO 465. LRET was
measured using saturating concentrations of full agonist (Glycine) and two partial
agonists (D-cycloserine, DCS and 1- aminocyclopropane-1-carboxylic acid, ACPC) that
showed varying amounts of activation. The final specific LRET lifetime is given in Table
4; this data was obtained upon subtracting the background thrombin digested lifetime.
IV. Results and Discussion
a. Modifications introduced to the full length NMDA receptor for LRET studies: The full
length NMDA receptors were used to study the mechanism of cleft closure. Both the
GluN1 and GluN2A subunits of the NMDA receptor were modified in order to eliminate
any single non-disulphide bonded accessible cysteines. Residues C2 and C459 in
GluN1 and C204, C399 and C460 in GluN2A were mutated to serine. These modified
subunits were referred to as GluN1* and GluN2A* and were in turn used for LRET
studies by introducing cysteines that enabled labeling using a maleimide derivative of
donor and acceptor fluorophores. The integrity of the plasmid after mutagenesis was
verified by sequencing and the mutants were characterized using TEVC to ensure their
functionality.
b. Mechanism of activation at GluN2A subunit of NMDA receptor : The observed LRET
lifetime and distance for GluN1*:GluN2A*N404C-Th, V713C mutant decreased from
39.4±0.6 Ǻ for the Apo state to 35.1±0.8 Ǻ for the full agonist glutamate-bound form
indicating that the cleft closes around 4 Ǻ upon binding of full agonist. While the lifetime
and corresponding distance for the partial agonist (HQ) was 37.1±0.4 Ǻ, this distance is
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indicative of a partially stabilized cleft with a difference of 2 Ǻ between apo and HQ
bound form. Interestingly, the antagonist (DLAPV) stabilized conformation with a
distance of 38.9±0.4 was very similar to the open cleft seen for the unligated apo state
of the receptor. Therefore, based on the LRET distances it can be concluded that there
is a negative correlation between the extent of cleft closure and the extent of activation
with full agonists bound receptors having a shorter distance and partial agonist bound
receptors having longer distances. These results support the cleft closure hypothesis
that is also observed for AMPA and kainate subtype of glutamate receptors where the
extent of cleft closure acts as the major coupling mechanism by which agonists mediate
activation (70, 71).
c. Mechanism of activation at GluN1 subunit of NMDA receptor: Based on the crystal
structures, it was previously proposed that the GluN1 subunit could follow a two-state
model with a shift in equilibrium between the closed and open cleft states. However, the
LRET lifetimes do not support this model since the lifetimes do not require two
exponentials and can be fit using a single exponential decay (Table 4). However, if
there is a large overlap between the states the protein probes in the apo and other
ligated states, then differentiation of the two forms becomes unfeasible using LRET.
Also, even in the AMPA subtype of glutamate receptors there are several mutants that
show a deviation from the cleft closure hypothesis. NMR and single molecule FRET
experiments on these mutants have been performed and they do not support the twostate model and instead indicate other mechanisms such as the dynamics of the
protein, and differences in specific interactions such as hydrogen bonds to likely play a
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Figure 25 Dependence of cleft closure versus extent of activation for the ABD of
GluN1*(open red squares) and GluN2A* (closed squares) subunits.
This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2011. Conformational changes in the agonist binding
domain of NMDA receptors. Journal of Biological Chemistry 286(19):16953-7. Copyright
the American Society for Biochemistry and Molecular Biology.
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role in the differences in activation by different ligands (54, 73-76). Likewise, although
we observe a correlation between the average extent of cleft closure and activation for
the GluN2A subunit, the dynamics and specific interactions at the level of side chains
may also play a role in activation for this subunit (75).
d. Statistical evidence regarding significance of differences in the calculated LRET
distances: A two-tailed t-test was performed for statistical analysis of differences in the
measured LRET distances and a p value of ≤0.05 was considered significant. For the
GluN2A subunit, the measured LRET distance decreased from 39.4±0.6 Ǻ for the Apo
form to 35.1±0.8 Ǻ for the glutamate-bound state. The two-tailed test yielded p=0.0017
thus indicating a statistically significant 4 Ǻ decrease in cleft closure between the Apo
and full agonist bound form. Likewise, the LRET distance for the partial agonist (HQ)
was 37.1±0.4 Ǻ with a statistically significant difference of 2 Ǻ between apo and HQ
bound form. The two-tailed test p value was 0.0052. On the other hand for the GluN1
subunit, the two- tailed test p value for difference in LRET distances measured between
the full agonist (glycine) and partial agonists (DCS/ACPC) bound forms is greater than
0.05 and hence considered to be statistically insignificant.
V. Future Experiments
The results based on the LRET investigations on the full length NMDA receptors
suggest that the extent of cleft closure could be the major coupling mechanism for
activation specifically for the glutamate binding GlUN2A subunit of NMDA receptor; it is
still unclear what contribution the glycine binding GluN1 subunit makes. Also since the
LRET based distances are ensemble measurements there is still a possibility that other
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factors like dynamics of the protein and side chain interactions could play a promising
role. Hence, to further examine the specific mechanism of activation detailed structural
investigations like single molecule FRET (smFRET) should be performed on both the
GluN1 and GluN2A subunits using the spectrum of agonists similar to the ones
employed earlier in the section.
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Chapter 6— Part III: Examining the conformations explored by the agonist
binding domain of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionate)
subtype of glutamate receptors.

Reproduced in part with permission from Landes, C.F., Rambhadran, A., Taylor, J.N.,
Salatan, F., and Jayaraman, V.

2011. Structural landscape of the isolated ligand

binding domain of single AMPA receptors. Nature Chemical Biology, 7(3):168173.Copyright 2011 Nature Publishing Group.
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I. Mechanism of activation in AMPA receptors
The mechanism by which the agonist induces activation and eventually desensitization
still remains an elusive question for the glutamate receptor family although

different

mechanisms have been proposed. The initial crystal structures of the soluble ABD of
the GluA2 subunit of AMPA receptors displayed a graded bilobed cleft upon binding
agonists of varying efficacy (49, 53, 54, 70, 77). In the Apo state, the cleft is fully open
and there is no current associated with this state. Current measurements were recorded
using the full length receptor expressed in HEK- 293 cells and electrophysiological
recordings were performed in the absence and presence of partial and full agonists. In
the partial agonist bound state, the cleft is partially closed (12 degree more closed than
in the apo form) and the currents associated with this state are intermediary. Finally,
when a full agonist like glutamate is bound, the cleft is closed the greatest (20 degrees
more closed than the apo state) and the corresponding current is maximum eliciting the
greatest activation. Antagonists, stabilize the cleft in an open form similar to the apo
state thus keeping the channel closed. Based on these structural and other functional
electrophysiological studies it has been proposed that the amount of cleft closure is the
primary mechanism by which activation occurs in these receptors (77).
However, there are several exceptions to the cleft closure hypothesis. According to the
crystal structures, kainate acts as partial agonist since it gets sterically hindered at the
ABD between residues L650 and Y450 (63, 78). Mutations at these residues, especially
to those amino acids that are smaller and flexible are therefore expected to make the
cleft more flexible, thereby allowing kainate to lodge deeper in the cleft and cause
greater activation compared to the wild type. Specifically, the L650T (Leucine 650 to
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Threonine) mutation has a profound effect on the AMPA receptor activity. For this
mutant, as expected, kainate induced activation is higher but ironically AMPA activation
is lower (similar to that of a partial agonist) even though the cleft is closed to the same
extent as when glutamate is bound which causes greater activation in the wild type.
Likewise, for the full agonist glutamate bound T686S mutant, the activation is only
partial for the same degree of cleft closure similar to the wild type. In addition, solution
based NMR studies on the different halogen substituted willardiines showed no
significant differences in the extent of cleft closure even with different degrees of
activation (76).
There are several limitations to the current approaches taken to study protein. While
crystal structures provide an initial insight into the lowest energy state structure of the
protein, ensemble LRET investigations measurements only yield the average of the
various states explored by the protein (63). Therefore, to gain a more complete
understanding it is vital to determine the range of states that the protein visits. In this
chapter we have used smFRET (single molecule fluorescence resonance energy
transfer) to directly measure all the configurations that the protein explores in the GluA2
agonist binding domain (GluA2- ABD) both in the apo and glutamate bound state for the
wild type protein and T686S mutant protein.
The T686 is involved in stabilizing the cleft via cross cleft hydrogen bonding, thus when
the threonine residue is mutated to a serine, it causes destabilization of the cleft. The
result is a floppy and unstable dynamic protein (78). Previous investigations of the ABD
with the T686 mutants have revealed that this mutant deviates from the cleft closure
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Figure 26 Extent of cleft closure in the ABD of glutamate receptor plotted as a function
of activation for wild type and mutants (T686S and L650T) that deviate from the cleft
closure hypothesis. Adapted from Ramanoudjame, G. et.al., 2006 (63, 79).
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hypothesis since the protein is more flexible and thus explores configurations that are
futile in terms of being able to mediate channel opening even though the crystal
structures point to a closed cleft. These findings correlate well with electrophysiological
measurements performed on this mutant protein where even in the presence of the full
agonist glutamate the activation resembles that of a partial agonist (78).
II. Experimental set- up for the smFRET experiments
The purified Histidine tagged GluA2-ABD protein was immobilized on a
PEGylated

glass

coverslip

surface

via biotin-streptavidin-antiHIS-HIS

chemical

interaction (Figure 27). This interaction was achieved using a Biotin conjugated Anti- His
antibody coupled to the GluA2 protein which was later allowed to react with streptavidinbiotin PEGylated cover slip surface. Streptavidin acted as the linker connecting the
biotin-PEG slide and the biotin-Anti-His Ab – GluR2-ABD. This procedure maximizes
both the conformational freedom of the two domains while minimizing nonspecific
protein/dye chemistry reactions. Maleimide derivatives of Alexa555 and Alexa647 were
employed to label the GluR2- ABD protein via two Cysteine mutations that replaced
T394 and S652 amino acids respectively. This particular mutant was chosen based on
previous work performed by the Jayaraman lab where ensemble LRET measurements
were performed (63, 80). Also, the mutations introduced were confirmed by whole cell
recordings to not interfere with channel functioning in the full length GluA2 receptor.
The immobilized, dye-labeled GluA2-ABD protein was then placed on a micro-reaction
chamber through which buffer solutions with and without the ligand was perfused via
syringe pumps.
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Figure 27 Set- up for immobilization of labeled GluA2-ABD for smFRET experiments.
Reproduced in part with permission from Landes, C.F., Rambhadran, A., Taylor, J.N.,
Salatan, F., and Jayaraman, V.

2011. Structural landscape of the isolated ligand

binding domain of single AMPA receptors. Nature Chemical Biology, 7(3):168173.Copyright 2011 Nature Publishing Group.
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The micro- reaction chamber was constructed by placing a coverslip with two ports on
top of the biotin-PEG glass slide. The two ports served as inlet and outlet ports for the
flow system. In order to minimize dye photobleaching an oxygen scavenging system
was employed. This solution was composed of 3% β-D-(+)-glucose (Sigma), 0.1 mg of
glucose oxidase per ml of solution, 0.02 mg of catalase per ml of solution, 2 mM MgCl2,
and saturated solution of Trolox powder (6-hydroxy-2,5,7,8-tetramethylchroman-2carboxylic acid). The buffering solutions used for the experiments comprised of
phosphate buffered saline solution with 1 mM glutamate in the case of the glutamate
experiments.
FRET Instrumentation
A schematic of the scanning confocal smFRET instrumentation is shown in Figure 28.
The micro chamber holding the sample is perched on top of a closed-loop x-y-z piezo
stage with 100 x 100 x 20 µm travel range and 1-nm specificity. An incident light of 532nm generated using solid state laser light was used to excite the sample. The power of
the laser light was in turn adjusted using neutral density filters. The excitation light has a
Gaussian profile beam at the sample juncture. This was achieved by expanding the
excitation light to overfill the back aperture of a FLUAR 100x 1.3 NA oil immersion
microscope objective. Fluorescence was collected by the objective and a dichroic mirror
separated the incident excitation light. The signal was later passed through a second
dichroic mirror (640-nm high-pass filter) to separate the donor and the acceptor
emission. The resulting donor and the acceptor fluorescence signals were collected by
two avalanche photodiode detectors respectively.
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Figure 28 Scanning confocal smFRET instrument set- up.
Reproduced in part with permission from Landes, C.F., Rambhadran, A., Taylor, J.N.,
Salatan, F., and Jayaraman, V.

2011. Structural landscape of the isolated ligand

binding domain of single AMPA receptors. Nature Chemical Biology, 7(3):168173.Copyright 2011 Nature Publishing Group.
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Data Collection and Analysis
The emission intensity trajectories were collected at a 1-ms resolution and later
binned up to 10 ms to enhance the S/N ratio. The fluorescence signals of the donor (ID)
and the acceptor (IA) were collected until the fluorophores were photobleached. The
apparent FRET efficiency (EA) was calculated using the following equation:
  



 

(1)

The distance between the two fluorophores was calculated with the following equation:


  1  



Where:

(2)

R = is the inter-dye distance, and R0 = is the Förster radius, which, for the

Alexa 555-Alexa 647 pair, is approximately 5.1 nm.
III. Structural landscape of the GluA2- glutamate bound form
The ensemble histogram for the GluA2 in the glutamate bound form is compiled
using many single molecule measurements for statistical analysis (Figure 29). The
average FRET efficiency for the glutamate bound form is 0.80 and this corresponds to
an inter-dye distance of 40.5 Å. Since the protein construct containing the T394C and
S652C mutations is similar to the protein that the Jayaraman lab had used for
performing ensemble FRET studies using maleimide derivatives of Terbium chelate and
Fluorescein, it becomes feasible to compare the average distance obtained using
smFRET technique to the ensemble LRET distance measured previously. The average
distance matches almost exactly to that estimated in the ensemble FRET
measurements, of 40.8 Å (63).
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Figure 29 Denoised histogram for the glutamate bound GluA2-Wild type protein along
with the crystal structure of GluA2-ABD protein highlighting the distance between the
two cysteine residues tagged with fluorophores.

Reproduced in part with permission from Landes, C.F., Rambhadran, A., Taylor, J.N.,
Salatan, F., and Jayaraman, V.

2011. Structural landscape of the isolated ligand

binding domain of single AMPA receptors. Nature Chemical Biology, 7(3):168173.Copyright 2011 Nature Publishing Group.

109

110

This comparison is important since it provides evidence that the labeling technique and
immobilization process did not affect either the cleft closure read out or the dye
chemistry. The comparison further underscores the fact that the distances from the
ensemble measurements on GluA2 protein are similar to the average smFRET values.
The smFRET histogram compiled from individual protein molecules allows for the
identification of the broad distribution and the range of states the protein probes even
when bound to glutamate (81, 82). The analysis indicated that there are primarily four
states that the protein explores each centered at apparent FRET values of 0.59 ± 5.8%,
0.72 ± 4.8% , 0.81 ± 4.2%, and 0.90 ± 3.8% . This data is the first experimental
evidence that has been performed on single GluA2 protein molecules that provides
support to the complex free energy landscape predicted by Benoit and co- workers (83).
The distances between the attached fluorophores are provided in terms of FRET
efficiencies of these states. However, the source of the distance changes could not be
ascribed to a particular attribute; it could arise due to side chain rearrangements,
hydrogen bond changes causing alterations in the backbone orientations etc (54, 75,
80). Hence, the precise nature of the conformational change associated with these
distances changes cannot be determined using these measurements.
The trajectories of the single FRET molecules are collected in 1 ms time bins and
further binned to 10 ms for data analysis, so that the fastest events that can be
measured are at least 10 ms in lifetime. Under such conditions, glutamate unbinding or
binding which typically occurs 1-2 orders of magnitude faster than the time scale of our
experiments cannot be measured, and we can consider glutamate to be in its
equilibrium bound state during the time scale of our measurements. The rates thus
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extracted here can be compared to NMR experiments performed on the same protein
that focused on similar phenomena (54, 73, 84). The NMR experiments found that
stabilization of the ABD occurred on time scales that are of the order of ms or longer.
These time scales therefore cannot be compared to those obtained, for example, via
channel conductance experiments that typically measure channel opening /closing
dynamics of full length membrane proteins. These measurements explore the dynamics
after ligand binding and initial cleft closure caused by agonist binding. To obtain a more
rigorous analysis of the rate constants associated with conformational exchange would
require a combination of more data points and increased time resolution of the
experiments.

IV. Structural landscape of the GluA2 in the Apo state
In a manner similar to the glutamate bound experiments described in the
previous section, data was collected for the apo GluA2 -ABD protein. As expected from
crystallographic and ensemble FRET experiments, the overall structure of the protein in
the apo state is more open (63, 70, 85). This conformation is evident from an observed
decrease in the average smFRET value for the apo GluR2-ABD, as shown in Figure 29.
Also the overall spread in the data, expressed in terms of standard deviation, indicates
that the protein explores a broader potential landscape than when bound to glutamate.
These observations have been previously predicted by simulations performed by Benoit
and co workers (83). Five-states were required to appropriately depict the data, as
shown in Figure 29. These states were found to be centered at apparent FRET values
of 0.54 ± 7.3%, 0.65 ± 6.1%, 0.75 ± 5.2%, 0.84 ± 4.7%, and 0.94± 4.2%.
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Figure 30 Denoised histogram for the Apo GluA2-Wild type protein along with crystal
structure of GluA2-ABD apo protein highlighting the distance between the two cysteine
residues tagged with fluorophores.

Reproduced in part with permission from Landes, C.F., Rambhadran, A., Taylor, J.N.,
Salatan, F., and Jayaraman, V.

2011. Structural landscape of the isolated ligand

binding domain of single AMPA receptors. Nature Chemical Biology, 7(3):168173.Copyright 2011 Nature Publishing Group.
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There are two possible reasons for the identification of 5 states for the apo GluA2-ABD
protein. The first comes from an examination of the 1-dimensional free energy plot
explained by Benoit and co-workers (83).

Although the curve for the Apo protein

contains four inflection points that indicate local free energy minima, there are additional
points where the curve flattens without actually inflecting. Changes in temperature or
ionic conditions could shift the equilibrium enough to stabilize additional local minima
states. Additionally, the order parameters used in the theoretical examination were
chosen for, among other qualities, their efficacy in extracting equilibrium distributions, as
opposed to dynamics (86). Different order parameters might lead to additional local
minima that comprise conformational intermediates. The predicted energy landscape
for the apo GluR2-ABD using smFRET is considerably broader than that of glutamate
bound protein indicating that the apo protein probes more states than the glutamate
bound protein.
V. Structural landscape of the GluA2- T686S mutant protein
The T686S mutant of GluR2-ABD lacks the hydrogen bonding that stabilizes the
inter cleft bonding, and hence serves as a good candidate to study the dynamics of the
protein using smFRET (78). As shown in Figure 31, the average smFRET value for the
mutant is 0.79 and the broad distribution of the states support the fact that the mutant is
more open overall even in the presence of glutamate. The distribution could be best fit
with a five-state model. The states identified are 0.39 ± 12%, 0.54 ± 8.7%, 0.68 ± 6.9%,
0.82 ± 5.7%, and 0.96 ± 4.9%.
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Figure 31 Denoised histogram for the T686S mutant GluA2- protein.
Reproduced in part with permission from Landes, C.F., Rambhadran, A., Taylor, J.N.,
Salatan, F., and Jayaraman, V.

2011. Structural landscape of the isolated ligand

binding domain of single AMPA receptors. Nature Chemical Biology, 7(3):168173.Copyright 2011 Nature Publishing Group.
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VI. Results and Discussion
The data obtained from the smFRET experiments for the average FRET
efficiency and the corresponding distances match very well with the previous ensemble
FRET investigations performed on the apo and Glutamate bound GluA2-ABD protein
(63). This correlation provides sufficient validity of the smFRET data. In Table 5, a
comparison is drawn between the average FRET/ distances with most probable state
FRET / distances obtained from the smFRET investigations. While for the Apo GluA2ABD protein the overall dynamics reveal that the 0.65 state is the most probable state.
This conformation is in stark contrast to the glutamate-bound GluA2-ABD protein, where
the closed form is favored resulting in 0.81 state being most prevalent.
From the table it can also be understood that the most probable conformation
can differ from the average conformation (70). Further, these observations are
correlated to changes seen in the crystal structure of GluA2-ABD between the Apo and
Glutamate bound protein. As seen from the table, the most probable state is in good
agreement with the crystal structure distances. This striking correlation further
strengthens the analysis and also addresses the differences seen between the smaller
changes reported earlier using ensemble FRET data to those observed in the crystal
structures.
An interesting aspect of the smFRET histograms is that they provide the overall
spread of the various states of the protein. This spread indicates that even in the
glutamate bound state, the protein is not rigidly locked as expected according to the
crystal structure. In addition, the smFRET data also demonstrate that the protein in the
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Table 5 A comparison of distances obtained via the smFRET experiments, traditional
ensemble FRET investigations and X-ray structures.
Reproduced in part with permission from Landes, C.F., Rambhadran, A., Taylor, J.N.,
Salatan, F., and Jayaraman, V.

2011. Structural landscape of the isolated ligand

binding domain of single AMPA receptors. Nature Chemical Biology, 7(3):168173.Copyright 2011 Nature Publishing Group.
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Method

Points of Measurement
between residues 394 and
652

Apo
GluR2ABD (Å)

Glutamate
bound
GluR2LBD (Å)

Difference
in distance
(Å)

X-Ray7,36

Cα to Cα

36

30

6

Ensemble
FRET14

Average distance between
Donor :Acceptor

45

41

4

smFRET

Distance between Donor
:Acceptor for most probable
conformation

46

40

6

smFRET

Distance between Donor
:Acceptor for average
conformation

43

40

3
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lack of an agonist that is in the apo form explores a broader landscape. Such broad
distribution of smFRET values observed is consistent with the landscape predicted by
simulations (83). For the glutamate bound form of the T686S mutant, the closed form is
nearly the same as that of the wild type glutamate-bound protein. This result is in
agreement with the crystal structure of glutamate bound T686S, where a closed cleft
similar to that observed for the wild type glutamate bound protein is seen.
However, what is observed from the T686S GluA2-ABD histogram is that the
mutant populates a broader range of distance distributions and more importantly
accesses states that are more open than the glutamate bound wild type protein GluA2ABD. These results indicate that the dynamics and the landscape that the protein
probes play a vital role in translating conformational changes to efficacy. Also based on
the simulations study, it was suggested that although the overall agonist-bound closed
form is destabilized in the T686S protein relative to the wild type, the mutation also
decreases steric hindrance in the cleft closure step(86)(85)(84)(83). This difference
results in a structure that is less rigid, and capable of exploring a wider range of both
open and closed cleft states, this stucture is what is observed in the smFRET
investigations.
In conclusion, the smFRET analysis of GluA2-ABD determined that the
glutamate-bound form is not a rigid, locked conformation, but instead is comprised of
multiple conformations of varying efficiencies. In addition, comparison of the apo and
T686S mutant form allowed the hypothesis that there is an optimal protein flexibility that
informs the functions of the seemingly disparate processes of activation and
desensitization of the protein. In essence, the investigations illustrate that activation is
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dependent not on a rigid closed cleft, but instead on the probability that a given subunit
will occupy a closed cleft conformation, which in turn is not only determined by the
lowest energy state but by the range of states that the protein explores.
VII. Future Experiments
The establishment of the smFRET experimental set –up has provided an ideal platform
to probe the dynamics of the range of states the protein explores and thereby draw
conclusions on the mechanism of activation of these receptors. Similar investigations on
the NMDA subtype of glutamate receptors, that is the GluN1- ABD and GluN2A- ABD
will be highly resourceful in establishing why the glycine binding GluN1 subunit behaves
differently and doesn’t follow the cleft closure hypothesis. By probing the range of states
the GluN1-ABD protein explores in the presence of full and partial agonists we can
determine the mechanism of activation in this subunit and directly draw a comparison to
correlate the glutamate binding GluN2A –ABD role. Based on the previously established
LRET results for the cleft closure in NMDA receptors, we hypothesize that the spread
for the GluN1-ABD will be much broader similar to the distribution observed for the
T686S mutant of GluA2-ABD. While on the other hand, the GluN2A-ABD will have a
much narrower spread. Likewise, studies can be extended to examine the role of
accessory proteins like Trans- membrane AMPA receptor regulatory proteins (TARPS)
to determine their role in AMPA receptor trafficking and activation.
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Overall Conclusions
Remembering the house you grew up in as a child, the friends you had in high school or
the name of your first dog is all possible due to a family of proteins called glutamate
receptors that are constantly at work in the human brain. The primary function of this
protein is to enable neurons (or nerve cells) in our body to communicate with one
another. It is this communication that makes it possible for us to learn, remember,
memorize and recall events and happenings in our everyday life. There are many
occasions when the relaying of information breaks down due to excessive uncontrolled
firing of the nerve cells. This leads to a plethora of problems including dementia,
depression, learning and memory loss to name a few. Studies have implicated the
glutamate family of proteins, specifically the NMDA (N-methyl D-aspartate) receptor
subtype, as a key player in various neuronal disorders such as Alzheimer’s,
Huntington’s or ALS (Amyotrophic lateral sclerosis) that manifest due to degeneration of
neuronal cells. In fact Alzheimer’s disease (AD) is the most common form of dementia
and is estimated tobe the fourth largest cause of death for people over 65 years of age
in the US. There are 5.3 million Americans who suffer from this progressive and fatal
disease. AD destroys brain cells resulting in memory loss and problems with thinking
and behavior that drastically affect the quality of life. However, there are currently only
four FDA approved medications to treat the cognitive degeneration manifested in AD
patients. Memantine, an antagonist that blocks one subtype of glutamate receptors is
one of those drugs and is only moderately efficient in treating moderate to severe forms
of AD.
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Hence there is a pressing need to develop antagonists or drugs that specifically target
these receptors thereby preventing neuronal injury and cell death. A major hurdle
towards the development of target drugs has been the lack of a clear understanding of
the mechanism by which NMDA receptors are activated.
NMDA receptors are tetrameric with two glycine binding (GluN1) and two glutamate
binding (GluN2A-D) subunits arranged as a dimer of dimers. Glycine and glutamate
binding to an extracellular agonist binding domain initiates a series of conformational
changes resulting in the formation of a central cation selective transmembrane channel.
This process of channel opening can be inhibited and
modulated allosterically by the binding of small molecules to the extracellular N-terminal
domain adjacent to the agonist binding domain. In this dissertation, I have addressed
the question of the specific arrangement of subunits in the NMDA receptor and how
agonists activate the receptor using LRET as a molecular ruler.
Luminescence resonance energy transfer (LRET) is a widely used technique to
measure large scale conformational changes in proteins. Using a combination of
agonists with varying efficacies, mutant, and wild type proteins, I have determined that
the GluN1 subunits are arranged across from each other in a diagonal manner in a
functional NMDA receptor. In addition, I have confirmed that the mechanism of
activation is conserved among the different subtypes of glutamate receptors.
The LRET investigations were complemented by biochemical and electrophysiological
investigations and thus allow us to draw direct correlations between structure and
function in this important protein.

124

The results from the structural studies combined with the functional data have yielded
invaluable information on the mechanism of NMDA receptor activation. A schematic of
the proposed mechanism of activation and inhibition in NMDA receptors is shown in
Figure 32. The proposed subunit arrangement and distance constraints using LRET
can be used as a model for the NMDA receptor structure and model compounds can be
screened for their potential to either activate or inhibit the receptors using conventional
docking methods. Further, cleft closure has been shown as the primary mechanism of
activation using LRET measurements; this can be used as a powerful tool to screen
various modulators/candidate drugs to determine their efficacy on the NMDA receptors.
By understanding the molecular mechanism of channel function, we will thus be able to
aid in future drug design with the potential to inhibit the protein in the case of stroke or
activate this important class of receptors in cases where we want to enhance memory.
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Figure 32 Mechanism of inhibition in NMDA receptors: The binding of agonist to the
ABD causes cleft closure which in turn places a stress on the linker connecting the
transmembrane domain, this causes channel opening (activation). The binding of
modulators/inhibitors to the ATD causes cleft closure of the ATD, this leads to a
separation of the linker region connecting ATD and ABD, causing the decoupling of
ABD dimer interface eventually causing the channel to close (inhibition). This inhibition
is stabilized by dimer interactions at the ATD.
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Appendix
This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2010. Subunit arrangement in N-Methyl-D-aspartate
(NMDA) receptors. Journal of Biological Chemistry 285(20):15296-301. Copyright the
American Society for Biochemistry and Molecular Biology.

This research was originally published in Journal of Biological Chemistry. Rambhadran,
A., Gonzalez, J., Jayaraman, V. 2011. Conformational changes in the agonist binding
domain of NMDA receptors. Journal of Biological Chemistry 286(19):16953-7. Copyright
the American Society for Biochemistry and Molecular Biology.
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I. Molecular Biology
a. ∆N*- NMDA Receptor
The plasmid for the GluN1 and GluN2A full length receptor was provided by Dr.
Nakanishi. This plasmid was modified by deleting the Amino Terminal domain (ATD),
residues 5-357 for GluN1 and 1-385 for GluN2A. A non- disulphide bonded accessible
cysteines were mutated to serine residues. Residues C459 in GluN1 and C399 and,
C460 on the extracellular side of GluN2A were changed to serines, producing modified
∆GluN1* and ∆GluN2A* receptors. Mutations in the plasmids were introduced using the
Stratagene QuikChange site-directed mutagenesis kit (Stratagene, CA). All constructs
were cloned in pcDNA3.1 (+) or pGEM vector and the integrity of the plasmid was
confirmed by sequencing.
b. GluN1*: GluN2A* Receptor
For cleft closure experiments, the full length GluN1 and, GluN2A were used and
modified such that there are no external non- disulphide cysteines accessible. To
achieve this, C2 and C459 in GluN1 and C204, C399 and C460 in GluN2A were
mutated to serines. The background modified construct was referred as GluN1*:
GluN2A* receptor and was cloned in pGEM vector.
c. RNA synthesis for oocyte injection
The mMessage mMachine Kit (Ambion) was used in the in vitro synthesis of
capped RNA. In brief, for one reaction (20 µL), 1 µg of linearized mutant DNA is used.
Upon linearizing, the DNA is cleaned via gel-extraction kit to remove impurities and the
linear DNA is eluted in nuclease-free water. Further, 10 µL of 2X NTP/CAP, 2 µL of 10X
sample reaction buffer, 2 µL of the respective enzyme(T7 RNA polymerase) along with
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necessary volume of nuclease-free water to make up the final volume to 20µl. This
reaction mix is incubated at 37 °C for 2 hours. Then, 1 µL of TURBO DNase is added to
remove any template DNA contamination and further incubated at 37 °C for 15-30
minutes. Lithium chloride was used to precipitate the RNA. Typically, 30 µL of lithium
chloride is added and allowed to chill overnight at -20 °C for a minimum of 5 hours. The
RNA is later precipitated by centrifuging at max speed to isolate the pellet, washed with
70% ethanol, and finally resuspended in nuclease-free water to desired concentration.
The RNA is later quantified, run on an agarose gel to ensure quality and size, and
stored in aliquots at -70°C until further use.
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II. Xenopus oocyte extraction and preparation
African clawed frogs were used as the source of oocytes. Frogs are
anesthesized using 1-2 g/L of tricaine methane sulfonate (MS222) powder that is
dissolved in deionized autoclaved water, buffered to pH of 7.5 using 5mM Hepes (1.192
g/L) and sodium bicarbonate. This solution of MS222 is always prepared fresh and is
filter-sterilized and autoclaved prior to use. The frog is bathed in this solution to enable
anesthetization.
To perform non-survival frog surgery and oocyte harvest, aseptic techniques are
used in a special area designated for frog procedures. In brief, the frog is placed in a
container with anesthesia (tricaine methane sulfonate) in water. After about 15 minutes,
the frog is kept on a tray covered with ice and saran wrap. This induces hypothermia
and thus prolongs the analgesic effect. The anesthetized frogs are verified by
disturbance either by pinching their toes and gently inverting them. The surgical
procedure begins by making a small incision (usually around 0.5cm) in the lower left or
right abdomen. The abdominal region is then opened and ovaries containing
approximately 200-300 oocytes are removed with the help of forceps.

To finally

euthanize the frog, the frog is decapitated and pithed while under the anesthetic effect
or is given an anesthetic overdose (>2.5 g/L).
To perform survival surgery on the frogs, strict aseptic procedures are employed.
Surgical gloves, and sterile/autoclaved instruments are used. All surgical procedures
are performed in areas designated for surgery and they were maintained under aseptic
conditions. Pre-surgery preparations included sterilizing surgical instruments with 70%
ethanol and flaming. The frog is anesthetized by immersion in MS222 solution for 15 to
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30 minutes and is verified by frog’s response to disturbance. Anesthesia will persist for
a minimum of 20 minutes. Frog is placed on tray with ice covered with saran wrap to
induce hypothermia and prolong the analgesic effect. Pre-wet paper towels are placed
in direct contact with the frog's skin to keep them moist. For the surgery, a small
incision (about 0.5cm) is made in the lower portion of the abdomen either to the left or
right. A similar incision is made through the frog’s abdominal muscle. Strand of eggs or
ovaries containing approximately 200-250 oocytes is removed with the help of forceps.
Following this removal, the incision is closed with absorbable suture after ensuring that
no air is trapped under the skin. The frog is then bathed in plain water 2-3 times and
placed head- up in a bucket without anesthetic to ensure their revival. The activity of the
frog is then monitored until it is actively swimming in the bucket. After a return to normal
activity, the frog placed in a separate tank to monitor its health for a few days. No
additional antibiotic treatments are necessary owing to a natural antibiotic in Xenopus
skin. A maximum of two survival surgeries is performed on a frog, one on each side of
the abdomen. If for some reason the frog is distressed, the veterinarians will be
informed and upon their recommendation the future course of action is determined.
Typical problems include a lack of vigorous swimming when disturbed, poor appetite, or
mild skin rash. In extreme cases, when no appropriate treatment is available, the frog is
euthanized. Also on occasions when a frog is unable to produce quality oocytes, it is
euthanized. Usually, there are few complications associated with surgery, but if there is
any sign of a problem, like uncontrolled bleeding, the frog is decapitated and pithed
under anesthetics or given an anesthetic overdose.
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Preparation of oocytes: Oocytes are defolliculated by incubation with 1-1.5
mg/ml collagenase. The collagenase is dissolved in Ca2+-free solution containing (in
mM): 83 NaCl, 2 KCl, 1 MgCl2, 5 HEPES, pH 7.5. The collagenase treatment is allowed
to proceed for 90-120 minutes. The preparation is then thoroughly rinsed with Barths
storage solution containing (in mM): 88 NaCl, 2.5 NaHCO3, 1.1 KCl, 0.4 CaCl2, 0.3
Ca(NO3)2, 0.8 MgCl2, 2.5 mM sodium pyruvate, 10 HEPES, pH 7.3, and 5 µg/ml
gentamicin; and stored overnight. Typically, stage V–VI oocytes are individually sorted
and injected with RNA of the modified receptor.
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III. Pre-blocking and Expression
Tthe oocytes are incubated for 2-3 days at 12 °C after injection, and then pre-labeled
with a maleimide derivative to block the inherent cysteines. β-maleimidopropionic acid
made in Barths storage solution is use at a final concentration of 100µM for 1 hour at
18°C. The oocytes are then washed extensively to get rid of the blocking reagent using
Barths solution. The pre- blocked oocytes are later allowed to express at 18 °C for 24 to
36 hours. At the end of 24-36 hours, the oocytes are labeled (described in the next
section).

134

IV. Labeling oocytes
For subunit arrangement measurements using ∆GluN1*:∆GluN2A* and mutants,
1µM terbium chelate was used for donor only experiments. While for donor: acceptor
LRET studies, either 1µM ATTO465 or Fluorescein in a 1:1 ratio is added
simultaneously along with donor for 1 hour to label the oocytes in Barth’s storage
solution. While for longer and shorter distance measurements 1µM (Ni-NTA)2Cy3 or
Ni2+, respectively, is added separately to the cuvette.

The membrane preparations

obtained upon lysing the oocytes were used for single channel recordings and LRET
experiments. Background LRET was measured 1-3 hours after the addition of Thrombin
(1-3 U, from Calbiochem, CA) to the cuvette and subtracted from the total LRET signal
to get the final specific signal from the receptors.
For the cleft closure experiments with GluN1*: GluN2A*, 1 µM terbium chelate is
used for donor-only experiments.

Membrane lysates for LRET experiments are

prepared as explained in the next section. The acceptor fluorophore used is either 1µM
maleimide derivative of ATTO 465 or Flurorescein. The acceptor is added along with
terbium chelate for donor:acceptor experiments in a 1:1 ratio. Background LRET was
measured 1-3 hours after the addition of Thrombin (1-3 U, from Calbiochem, CA) to the
cuvette and subtracted from the total LRET signal to get the final specific signal from the
receptors.
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V. Membrane Preparation
For LRET studies, approximately 300-500 labeled oocytes expressing modified
NMDA receptors are lysed by gently douncing in 1.5 mL of lysis buffer. The lysis buffer
consists of 20 mM Tris, pH 7.6, 200 mM NaCl, 1% Triton X-100, and EDTA-free
Complete Protease Inhibitor Cocktail (Roche). The lysed ooctyes are then spun at 5000
rpm for 20-30 minutes get rid of the cell debris and nuclear components, followed by a
13,000-15,000 rpm for 30 minutes at 4°C to collect the supernatant. The membrane
suspensions are resuspended in Barth’s storage solution to achieve final desired
volume.
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VI. Electrophysiology
Two-electrode voltage-clamp (TEVC) recordings were performed using the NPI
TEC amplifier (ALA Scientific, NY). Typically, the microelectrodes were filled with 3M
KCl and had resistances of 1-3 MOhms. A narrow flow-through recording chamber with
a volume of 75 µl was used to minimize the solution exchange time (ALA Scientific, NY).
The extracellular solution contained (in mM): 100 NaCl, 1 KCl, 0.7 BaCl2, 0.8 MgCl2, and
5 HEPES, pH 7.5 with NaOH. Currents were recorded with Cell Works software (ALA
Scientific, NY), exported and analyzed using Origin 4.0 (OriginLab, MA). Whole-cell
current recordings were performed as previously described (87).
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VII. Expression and labeling of the isolated ABD of GluA2
The GluA2-ABD plasmid was provided by Dr Eric Gouaux (Oregon Health and Science
University, Portland, OR). S652C, T394C and T686S mutations were introduced using
Quick Change Site- Directed Mutagenesis Kit (Stratagene). The GluA2-ABD and mutant
T686S –GluA2 ABD protein were expressed and purified as described by Armstrong et
al (53). In brief, the wild type and mutant protein were expressed in Escherichia Coli
Origami–B (DE3) cells and the Histidine tag containing proteins were subjected to
purification using Ni-NTA Hi Trap column (GE Healthcare). 0.1-0.5µM protein in
phosphate buffer with 1mM glutamate was used for labeling. Thiol- reactive maleimide
derivatives of Alexa 555 and 647 (Invitrogen) served as donor and acceptor probes. The
Alexa fluorophores are directly linked to the thiol group of the cysteines in the proteins
and no additional linkers are present between the fluorophores and the protein.
Unreacted excess dyes were removed by dialyzing extensively in either phosphate
buffer only for Apo experiments or in phosphate buffer containing 10mM glutamate for
glutamate bound single molecule experiments. Preparation of samples for the single
molecule experiments were performed as described by Hanson et al and is explained in
the next section.
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VIII. Sample preparation for smFRET experiments
Glass slides used for smFRET experiments are plasma cleaned to remove
impurities from the surface. Vectabond (Vector Labs), a proprietary aminosilane, was
used to amine functionalize the surface. The amine group of the Vectabond reacted with
the NHS ester group of O-[2-(N-Succinimidyloxycarbonyl)-ethyl]-O’-methylpolyethylene
glycol 5000 (NHS-PEG-5000 – Fluka)) and NHS-PEG-5000-Biotin (biotin-PEG – NOF
Corporation). The sample chamber was assembled by placing a coverslip with two ports
on top of the biotin-PEG glass slide(88, 89)(87, 88)(86, 87)(85, 86). The two ports were
used as inlet and outlet ports for the flow system. The GluA2-ABD was attached to a
biotin-conjugated anti-histidine monoclonal antibody (biotin-Anti-His Ab, Rockland). The
biotin-PEG slide was incubated with streptavidin (SA) solution. The SA served as the
linker between the biotin-PEG slide and the biotin-Anti-His Ab – GluA2-ABD.
An oxygen scavenging flow solution was prepared by following an established
protocol. The flow solution was composed of 3% (wt/vol) β-D-(+)-glucose (Sigma), 0.1
mg of glucose oxidase (Roche Applied Science) per ml of solution, 0.02 mg of catalase
(Roche Applied Science) per ml of solution, 2 mM MgCl2, and saturated solution of
Trolox powder (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; Fluka). The
Trolox powder was dissolved in PBS, and then subsequently filtered (90, 91). The final
flow solutions contained 10 mM glutamate in phosphate buffered saline solution in the
case of the glutamate-bound experiments.
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